XRAY DENTSPLY SIRONA Inc.
Dental Equipment & Supplies · Nasdaq · SEC CIK 818479 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-1.4%
TTM net income YoY86.3%
TTM EPS YoY86.1%
Revenue 3-yr CAGR-3.2%
Net income 3-yr CAGR—
Margins
Gross margin50.5%
Operating margin-1.5%
Net margin-3.4%
FCF margin2.9%
EBITDA margin7.9%
Returns
ROE-8.5%
ROA-2.2%
ROIC (approx.)-1.3%
Asset turnover0.66x
Leverage & solvency
Liabilities / assets73.9%
Debt / equity1.62x
Current ratio1.63x
Interest coverage-0.59x
Cash quality & payout
Operating cash flow / net income-2.25x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue4.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $3.68B | $3.79B |
| Cost of revenue | $1.84B | $1.83B |
| Gross profit | $1.84B | $1.96B |
| R&D expense | $150.00M | $165.00M |
| SG&A expense | $1.44B | $1.60B |
| Operating income | -$422.00M | -$879.00M |
| Interest expense | $88.00M | $69.00M |
| Pretax income | -$486.00M | -$936.00M |
| Income tax | $112.00M | -$26.00M |
| Net income | -$598.00M | -$910.00M |
| EBITDA | -$70.00M | -$530.00M |
| EPS (basic) | -3.00 | -4.48 |
| EPS (diluted) | -3.00 | -4.48 |
| Dividends declared per share | 0.64 | 0.64 |
| Weighted avg. shares (diluted) | 199.40M | 203.20M |
| Balance sheet | ||
| Cash & equivalents | $326.00M | $272.00M |
| Inventory | $642.00M | $564.00M |
| Current assets | $2.02B | $1.75B |
| PP&E, net | $861.00M | $766.00M |
| Goodwill | $1.15B | $1.60B |
| Intangibles | $974.00M | $1.21B |
| Total assets | $5.43B | $5.75B |
| Current liabilities | $1.34B | $1.59B |
| Short-term debt | $313.00M | $549.00M |
| Long-term debt | $2.02B | $1.59B |
| Total debt | $2.33B | $2.13B |
| Total liabilities | $4.09B | $3.81B |
| Shareholders' equity | $1.34B | $1.94B |
| Net debt | $2.00B | $1.86B |
| Shares outstanding | 199.60M | 198.80M |
| Cash flow statement | ||
| Operating cash flow | $235.00M | $461.00M |
| Capital expenditure | $131.00M | $180.00M |
| Free cash flow | $104.00M | $281.00M |
| Investing cash flow | -$132.00M | -$197.00M |
| Financing cash flow | -$80.00M | -$302.00M |
| Depreciation & amortization | $352.00M | $349.00M |
| Stock-based compensation | $33.00M | $39.00M |
| Dividends paid | $128.00M | $126.00M |
| Share buybacks | $0 | $250.00M |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.